Actinogen Medical’s Alzheimer Disease Trial Achieves Another Milestone

Biotech firm Actinogen Medical achieved another milestone as its first patient from the United Kingdom started treatment under the company’s Alzheimer’s disease or XanADu trial at St. Pancras Clinical Research in London.

Key Takeaways:

• First patient from the United Kingdom started treatment
• An estimated 50 million people worldwide are suffering from Alzheimer’s disease
• The cost of managing the illness is too expensive at US$250 Billion
• Actinogen Medical is conducting XanADu trial for Xanamem at locations in the US, UK and Australia

Biotech firm Actinogen Medical achieved another milestone as its first patient from the United Kingdom started treatment under the company’s Alzheimer’s disease or XanADu trial at St. Pancras Clinical Research in London.

A total of 174 patients are expected to take part in a trial that will be conducted at 20 research locations in the UK, United States and in Australia. However, only 18 sites have opened so far, with more than 50 patients already screened for the study.

“We are very pleased for our patients to participate in XanADu, a study of a novel new potential treatment for Alzheimer’s disease. St Pancras Clinical Research, located in the heart of London, has a catchment area across Greater London of more than 15 million people, and we are committed to undertaking high quality research through new clinical trials to enable enhanced health care in the future. Xanamem offers much promise in a disease area sadly lacking new, effective treatments.” Actinogen Medical CEO Dr Bill Ketelbey said.

Dr. Veronika Horvathova and Dr. Stuart Ratcliffe are among those working on the development of Xanamem at the St. Pancras Clinical Research. Xanamem is a new therapy being developed by Actinogen Medical for the treatment of Alzheimer’s disease, the leading cause of mortality in the UK. The therapy blocks too much production of the stress hormone cortisol which is highly concentrated in the brain’s frontal cortex and hippocampus.

“The XanADu trial represents another important step towards alleviating the burden of Alzheimer’s for millions of people worldwide and we look forward to working together with the St Pancras team in achieving this goal,” Ketelbey said.

Researchers believe that excess cortisol and chronic stress highly affect the brain resulting to Alzheimer’s disease. Managing the disease can be very costly at an estimated US$250 Billion. A lot of people are banking on the success of Xanamem considering that around 50 million people worldwide are suffering from Alzheimer’s disease.

Request Information